100 related articles for article (PubMed ID: 18668443)
21. Effect of Antioxidants in Medicinal Products on Intestinal Drug Transporters.
Kulkarni CP; Yang J; Koleske ML; Lara G; Alam K; Raw A; Rege B; Zhao L; Lu D; Zhang L; Yu LX; Lionberger RA; Giacomini KM; Kroetz DL; Yee SW
Pharmaceutics; 2024 May; 16(5):. PubMed ID: 38794309
[TBL] [Abstract][Full Text] [Related]
22. The apparent permeabilities of Caco-2 cells to marketed drugs: magnitude, and independence from both biophysical properties and endogenite similarities.
O'Hagan S; Kell DB
PeerJ; 2015; 3():e1405. PubMed ID: 26618081
[TBL] [Abstract][Full Text] [Related]
23. Use of in vitro ADME methods to identify suitable analogs of homosalate and octisalate for use in a read-across safety assessment.
Grégoire S; Moustié A; Lereaux G; Roussel-Berlier L; Hewitt N
J Appl Toxicol; 2024 Mar; ():. PubMed ID: 38539266
[TBL] [Abstract][Full Text] [Related]
24. Caco-2 cell methodology and inhibition of the P-glycoprotein transport of digoxin by Aloe vera juice.
Djuv A; Nilsen OG
Phytother Res; 2008 Dec; 22(12):1623-8. PubMed ID: 19003953
[TBL] [Abstract][Full Text] [Related]
25. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
Mease K; Sane R; Podila L; Taub ME
J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
[TBL] [Abstract][Full Text] [Related]
26. Validation of quinidine as a probe substrate for the in vitro P-gp inhibition assay in Caco-2 cell monolayer.
Patil AG; D'Souza R; Dixit N; Damre A
Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):115-9. PubMed ID: 21725799
[TBL] [Abstract][Full Text] [Related]
27. Optimization of the Caco-2 permeability assay to screen drug compounds for intestinal absorption and efflux.
Press B
Methods Mol Biol; 2011; 763():139-54. PubMed ID: 21874449
[TBL] [Abstract][Full Text] [Related]
28. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines.
Volpe DA
Future Med Chem; 2011 Dec; 3(16):2063-77. PubMed ID: 22098353
[TBL] [Abstract][Full Text] [Related]
29. TEER measurement techniques for in vitro barrier model systems.
Srinivasan B; Kolli AR; Esch MB; Abaci HE; Shuler ML; Hickman JJ
J Lab Autom; 2015 Apr; 20(2):107-26. PubMed ID: 25586998
[TBL] [Abstract][Full Text] [Related]
30. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels.
Anderle P; Niederer E; Rubas W; Hilgendorf C; Spahn-Langguth H; Wunderli-Allenspach H; Merkle HP; Langguth P
J Pharm Sci; 1998 Jun; 87(6):757-62. PubMed ID: 9607955
[TBL] [Abstract][Full Text] [Related]
31. The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model.
Takano J; Maeda K; Bolger MB; Sugiyama Y
Drug Metab Dispos; 2016 Nov; 44(11):1808-1818. PubMed ID: 27538919
[TBL] [Abstract][Full Text] [Related]
32. Caco-2 cells, biopharmaceutics classification system (BCS) and biowaiver.
Smetanová L; Stĕtinová V; Svoboda Z; Kvetina J
Acta Medica (Hradec Kralove); 2011; 54(1):3-8. PubMed ID: 21542416
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics.
Hughes J; Crowe A
J Pharmacol Sci; 2010; 113(4):315-24. PubMed ID: 20724802
[TBL] [Abstract][Full Text] [Related]
34. Establishment of optimized MDCK cell lines for reliable efflux transport studies.
Gartzke D; Fricker G
J Pharm Sci; 2014 Apr; 103(4):1298-304. PubMed ID: 24532159
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein mediated efflux in Caco-2 cell monolayers: the influence of herbals on digoxin transport.
Oga EF; Sekine S; Shitara Y; Horie T
J Ethnopharmacol; 2012 Dec; 144(3):612-7. PubMed ID: 23064285
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo pharmacokinetic characterization, chiral conversion and PBPK scaling towards human PK simulation of S-MRI-1867, a drug candidate for Hermansky-Pudlak syndrome pulmonary fibrosis.
Padilha EC; Yang M; Shah P; Wang AQ; Duan J; Park JK; Zawatsky CN; Malicdan MCV; Kunos G; Iyer MR; Gaucher G; Ravenelle F; Cinar R; Xu X
Biomed Pharmacother; 2023 Dec; 168():115178. PubMed ID: 37890204
[TBL] [Abstract][Full Text] [Related]
37. A Unique In Vitro Assay to Investigate ABCB4 Transport Function.
Temesszentandrási-Ambrus C; Nagy G; Bui A; Gáborik Z
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901890
[TBL] [Abstract][Full Text] [Related]
38. Mechanistic in vitro studies indicate that the clinical drug-drug interactions between protease inhibitors and rosuvastatin are driven by inhibition of intestinal BCRP and hepatic OATP1B1 with minimal contribution from OATP1B3, NTCP and OAT3.
Elsby R; Coghlan H; Edgerton J; Hodgson D; Outteridge S; Atkinson H
Pharmacol Res Perspect; 2023 Apr; 11(2):e01060. PubMed ID: 36811234
[TBL] [Abstract][Full Text] [Related]
39. Canine and feline P-glycoprotein deficiency: What we know and where we need to go.
Mealey KL; Owens JG; Freeman E
J Vet Pharmacol Ther; 2023 Jan; 46(1):1-16. PubMed ID: 36326478
[TBL] [Abstract][Full Text] [Related]
40. In Vitro Evaluation of P-gp-Mediated Drug-Drug Interactions Using the RPTEC/TERT1 Human Renal Cell Model.
Saib S; Hodin S; Bin V; Ollier E; Delavenne X
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):223-233. PubMed ID: 34935100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
